logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Edasalonexent for Duchene muscular dystrophy

< Back

Edasalonexent for Duchene muscular dystrophy

Drugs

Musculoskeletal

August 2020


Edasalonexent is currently in clinical development for the treatment of male paediatric patients with Duchenne muscular dystrophy (DMD). DMD is a rare genetic condition caused by a mistake or abnormality in a gene called dystrophin, located on the X chromosome (one of the two sex chromosomes). Chromosomes are tiny structures inside cells made from deoxyribonucleic acid (DNA) and proteins. Males have one X chromosome, while females have two X chromosomes. As males have one X chromosome, DMD is much more common in males. DMD is fatal condition with no cure. It causes progressive muscle weakness and often leads to loss of walking ability by the age of twelve, as well as problems with the heart and lungs. Current treatment options only target a particular mistake or abnormality and focus on slowing progression of the disease.
Edasalonexent is administered orally. It works by reducing the NF-κB activity, a protein that causes inflammation leading to muscle damage and prevention of muscle regeneration seen in patients with DMD. Edasalonexent is expected to reduce the muscle damage seen in DMD and enable muscle regeneration. If licensed, edasalonexent will provide a treatment option for male paediatric patients with DMD.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts